Dexamethasone opthalmic - Oculis Pharma

Drug Profile

Dexamethasone opthalmic - Oculis Pharma

Alternative Names: dexamethasone cyclodextrin nanoparticle eye drops; dexamethasone/γCD nanoparticle; DexNP

Latest Information Update: 29 Sep 2016

Price : $50

At a glance

  • Originator Oculis Pharma
  • Developer Oculis Pharma; Tel Aviv University
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Diabetic macular oedema; Glaucoma; Postoperative inflammation; Uveitis

Most Recent Events

  • 31 Aug 2016 Oculis Pharma has patent protection for its nanoparticle technology in USA and Europe
  • 16 Aug 2016 Oculis Pharma announces intention to submit applications for regulatory approval in USA and Europe
  • 16 Aug 2016 Oculis completes a phase II trial in Diabetic macular oedema in Japan before August 2016 (Opthalmic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top